Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Jun 30, 2010
Filed with the SEC on Aug 3, 2010 and accepted by EDGAR at Aug 3, 2010, 20:41 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2010-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2010-04-01 to 2010-06-30 | $31.6m | us-gaap:Revenues |
| Revenue | 6 months2010-01-01 to 2010-06-30 | $54.1m | us-gaap:Revenues |
| Research and development | 3 months2010-04-01 to 2010-06-30 | $155.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2010-01-01 to 2010-06-30 | $298.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2010-04-01 to 2010-06-30 | $40.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2010-01-01 to 2010-06-30 | $76.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2010-04-01 to 2010-06-30 | −$169.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2010-01-01 to 2010-06-30 | −$329.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2010-04-01 to 2010-06-30 | $3.7m | us-gaap:InterestExpense |
| Interest expense | 6 months2010-01-01 to 2010-06-30 | $7.6m | us-gaap:InterestExpense |
| Diluted EPS | 3 months2010-04-01 to 2010-06-30 | −$1.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2010-01-01 to 2010-06-30 | −$1.83 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2010-04-01 to 2010-06-30 | −$1.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2010-01-01 to 2010-06-30 | −$1.83 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2010-04-01 to 2010-06-30 | 200,397,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2010-01-01 to 2010-06-30 | 199,670,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2010-01-01 to 2010-06-30 | −$305.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2010-01-01 to 2010-06-30 | $12.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2010-06-30 | $337.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2010-06-30 | $1.00bn | us-gaap:AssetsCurrent |
| Total assets | At period end2010-06-30 | $1.65bn | us-gaap:Assets |
| Current liabilities | At period end2010-06-30 | $292.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2010-06-30 | $827.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2010-06-30 | $827.1m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001047469-10-006916. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.